Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under...
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced the election of Kathleen Tregoning to...
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the Jefferies...
Compass Pathways (NASDAQ:CMPS) executives said the company remains on track to target a fourth-quarter New Drug Application filing for COMP360, its synthetic psilocybin treatment candidate for treatment-resistant...
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will attend the RBC...
Compass Pathways (NASDAQ:CMPS) said it has begun a rolling New Drug Application submission for COMP360, its investigational psilocybin treatment for treatment-resistant depression, and is preparing for...
FDA granted Compass NDA rolling submission and review request, based on strength of Phase 3 data CNPV awarded for COMP360 in TRD, further accelerating...
Barchart Research What to Expect from CMPS Earnings CMPS Generated May 12, 2026 Current Price $9.37 EPS Estimate $$-0.45 Consensus Rating Strong Buy Average Move 8.00% Can Compass Pathways Justify Its...
Compass management will host a conference call at 8:00 am ET (1:00 pm UK)Â
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that Compass granted equity awards under...